Amarin Corp Plc (AMRN)

[eboomer2611]

Your response is not connected to reality as well.

I have worked with BP and they certainly would pay closer to 3-5 times peak sales for a blockbuster drug that has at least 10 years on patent and the ability to have other indications and some defenses like (ability to lock down supply). It is very likley that over time amost anyone on a statin should be take Vascepa and then there are people like me who are pretty healthy but are taking it because it does so much good with no risk.

I have been part of M&A in life sciences and you are disconnected here. Many BP are very interested in AMRN and they would pay a lot more than you have indicated. It may not be as high as others on the board think but it much higher than current price as everyone is waiting for AHA to see what is best estimate for peak sales. My brother is a top cardiologist speciality rep for a large company and his doctors are some of the top cardiologists (think presidents as patients). He has confirmed what others are - these guys think this is game changing and he knows his company and others are watching AMRN intently.

I can tell you from first hand experience that many BP have been operating on an acqusition strategy that is evolved from 5-10 years ago. The prevailing Board Room strategy was to buy many compelling pipelines or companies early on with the hope of finding some winners. Overall, this did not work for most of them. Many of them now aspart of their SOPs for M&A want to purchase more de-risked; specifically they are happy to pay much more down the line when the science works and they have no regrets about that. This is why no one took a flyer before Reduce It even if they were bullish on it. History has shown you are better served paying far more when you know what you have and can assess your ability to sell it and what you think it will do for you.

And $6B for a transformative drug that is going to change the landscape of cardio and is the first outcome study to real have this kind of potential since statins. You must be from Canada smoking some legal cannabis - please pass the pipe. I mean Novartis just paid $8.7B for Avexis which has a good potential drug but is orphan status and vascepa has a much larger potential.